ZURICH, June 22 (Reuters) - Novartis aims to help manufacture more than 50 million doses of BioNTech's COVID-19 vaccine in 2021 at its Stein, Switzerland fill-and-finish facility, the Swiss drugmaker said, after the European Union's drug regulator approved the bottling plant. (Reporting by John Miller Editing by Chris Reese)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
92.77 CHF | -0.42% | +0.16% | +9.31% |
04:43pm | Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating | MT |
08:07am | NOVARTIS AG : Berenberg remains Neutral | ZD |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.31% | 208B | |
+38.26% | 723B | |
+34.28% | 595B | |
-4.62% | 369B | |
+20.03% | 332B | |
+2.54% | 282B | |
+17.02% | 244B | |
-5.07% | 205B | |
-0.19% | 168B | |
+6.65% | 166B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis : aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021